Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022 Oct;26(40):1–144. doi: 10.3310/PLPU1526

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.

Rakesh Heer, Rebecca Lewis, Anne Duncan, Steven Penegar, Thenmalar Vadiveloo, Emma Clark, Ge Yu, Paramananthan Mariappan, Joanne Cresswell, John McGrath, James N'Dow, Ghulam Nabi, Hugh Mostafid, John Kelly, Craig Ramsay, Henry Lazarowicz, Angela Allan, Matthew Breckons, Karen Campbell, Louise Campbell, Andy Feber, Alison McDonald, John Norrie, Giovany Orozco-Leal, Stephen Rice, Zafer Tandogdu, Ernest Taylor, Laura Wilson, Luke Vale, Graeme MacLennan, Emma Hall
PMCID: PMC9639219  PMID: 36300825

Abstract

BACKGROUND

Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule required after initial treatment has associated costs for patients and the NHS. In photodynamic diagnosis, before transurethral resection of bladder tumour, a photosensitiser that is preferentially absorbed by tumour cells is instilled intravesically. Transurethral resection of bladder tumour is then conducted under blue light, causing the photosensitiser to fluoresce. Photodynamic diagnosis-guided transurethral resection of bladder tumour offers better diagnostic accuracy than standard white-light-guided transurethral resection of bladder tumour, potentially reducing the chance of subsequent recurrence.

OBJECTIVE

The objective was to assess the clinical effectiveness and cost-effectiveness of photodynamic diagnosis-guided transurethral resection of bladder tumour.

DESIGN

This was a multicentre, pragmatic, open-label, parallel-group, non-masked, superiority randomised controlled trial. Allocation was by remote web-based service, using a 1 : 1 ratio and a minimisation algorithm balanced by centre and sex.

SETTING

The setting was 22 NHS hospitals.

PARTICIPANTS

Patients aged ≥ 16 years with a suspected first diagnosis of high-risk non-muscle-invasive bladder cancer, no contraindications to photodynamic diagnosis and written informed consent were eligible.

INTERVENTIONS

Photodynamic diagnosis-guided transurethral resection of bladder tumour and standard white-light cystoscopy transurethral resection of bladder tumour.

MAIN OUTCOME MEASURES

The primary clinical outcome measure was the time to recurrence from the date of randomisation to the date of pathologically proven first recurrence (or intercurrent bladder cancer death). The primary health economic outcome was the incremental cost per quality-adjusted life-year gained at 3 years.

RESULTS

We enrolled 538 participants from 22 UK hospitals between 11 November 2014 and 6 February 2018. Of these, 269 were allocated to photodynamic diagnosis and 269 were allocated to white light. A total of 112 participants were excluded from the analysis because of ineligibility (n = 5), lack of non-muscle-invasive bladder cancer diagnosis following transurethral resection of bladder tumour (n = 89) or early cystectomy (n = 18). In total, 209 photodynamic diagnosis and 217 white-light participants were included in the clinical end-point analysis population. All randomised participants were included in the cost-effectiveness analysis. Over a median follow-up period of 21 months for the photodynamic diagnosis group and 22 months for the white-light group, there were 86 recurrences (3-year recurrence-free survival rate 57.8%, 95% confidence interval 50.7% to 64.2%) in the photodynamic diagnosis group and 84 recurrences (3-year recurrence-free survival rate 61.6%, 95% confidence interval 54.7% to 67.8%) in the white-light group (hazard ratio 0.94, 95% confidence interval 0.69 to 1.28; p = 0.70). Adverse event frequency was low and similar in both groups [12 (5.7%) in the photodynamic diagnosis group vs. 12 (5.5%) in the white-light group]. At 3 years, the total cost was £12,881 for photodynamic diagnosis-guided transurethral resection of bladder tumour and £12,005 for white light. There was no evidence of differences in the use of health services or total cost at 3 years. At 3 years, the quality-adjusted life-years gain was 2.094 in the photodynamic diagnosis transurethral resection of bladder tumour group and 2.087 in the white light group. The probability that photodynamic diagnosis-guided transurethral resection of bladder tumour was cost-effective was never > 30% over the range of society's cost-effectiveness thresholds.

LIMITATIONS

Fewer patients than anticipated were correctly diagnosed with intermediate- to high-risk non-muscle-invasive bladder cancer before transurethral resection of bladder tumour and the ratio of intermediate- to high-risk non-muscle-invasive bladder cancer was higher than expected, reducing the number of observed recurrences and the statistical power.

CONCLUSIONS

Photodynamic diagnosis-guided transurethral resection of bladder tumour did not reduce recurrences, nor was it likely to be cost-effective compared with white light at 3 years. Photodynamic diagnosis-guided transurethral resection of bladder tumour is not supported in the management of primary intermediate- to high-risk non-muscle-invasive bladder cancer.

FUTURE WORK

Further work should include the modelling of appropriate surveillance schedules and exploring predictive and prognostic biomarkers.

TRIAL REGISTRATION

This trial is registered as ISRCTN84013636.

FUNDING

This project was funded by the National Institute for Health and Care Research ( NIHR ) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 40. See the NIHR Journals Library website for further project information.

Plain language summary

Around 7500 people are diagnosed with early-stage bladder cancer in the UK each year. Early bladder cancer is contained within the bladder and has not yet invaded the bladder’s muscle wall or spread elsewhere in the body. The cancer will return (recur) in around half of people after initial treatment and they have to attend hospital for regular check-ups, with costs to both them and the NHS. The first step in treating early bladder cancer is surgery to remove the tumour. This surgery is normally performed under white light. Photodynamic diagnosis is a new technique in which a liquid is put into the patient’s bladder before surgery and a blue light is used during the operation. This causes the bladder cancer to fluoresce so that it can be seen more easily by the surgeon. The Photodynamic versus white-light-guided resection of first diagnosis non-muscle-invasive bladder cancer ( PHOTO ) trial aimed to find out whether or not using photodynamic diagnosis at initial surgery would reduce how often the cancer recurred and whether or not this could reduce the cost of treating early bladder cancer. A total of 538 people with early bladder cancer who had a medium to high chance of their cancer returning after treatment were enrolled in the PHOTO trial. They were included in one of two treatment groups, at random: 269 had photodynamic surgery and 269 had standard white-light surgery. People in both groups were monitored regularly for any recurrences, with further treatment as appropriate. After 3 years, 4 out of 10 people in each group had a recurrence of their bladder cancer. We found no difference between the treatment groups in the number of people with recurrences. We found no evidence of a benefit to patients, and the total costs of photodynamic surgery were higher than those of standard white light. We therefore recommend that it is no longer used in the treatment of this group of patients.

Full text of this article can be found in Bookshelf.

References

  1. Tandogdu Z, Lewis R, Duncan A, Penegar S, McDonald A, Vale L, et al. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. BMJ Open 2019;9:e022268. https://doi.org/10.1136/bmjopen-2018-022268 doi: 10.1136/bmjopen-2018-022268. [DOI] [PMC free article] [PubMed]
  2. Cancer Research UK. Bladder Cancer Statistics. 2020. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer (accessed June 2021).
  3. Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 2002;90:228–39. https://doi.org/10.1046/j.1464-410X.2002.02880.x doi: 10.1046/j.1464-410X.2002.02880.x. [DOI] [PubMed]
  4. Puente D, Hartge P, Greiser E, Cantor KP, King WD, González CA, et al. A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. Cancer Causes Control 2006;17:71–9. https://doi.org/10.1007/s10552-005-0389-0 doi: 10.1007/s10552-005-0389-0. [DOI] [PubMed]
  5. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 2011;105:1795–803. https://doi.org/10.1038/bjc.2011.430 doi: 10.1038/bjc.2011.430. [DOI] [PMC free article] [PubMed]
  6. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48. https://doi.org/10.1097/00000478-199812000-00001 doi: 10.1097/00000478-199812000-00001. [DOI] [PubMed]
  7. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006;97:301–5. https://doi.org/10.1111/j.1464-410X.2006.05976.x doi: 10.1111/j.1464-410X.2006.05976.x. [DOI] [PubMed]
  8. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524–7. https://doi.org/10.1016/S0022-5347(05)67916-5 doi: 10.1016/S0022-5347(05)67916-5. [DOI] [PubMed]
  9. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, Sole GM. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010;92:519–24. https://doi.org/10.1308/003588410X12664192076935 doi: 10.1308/003588410X12664192076935. [DOI] [PMC free article] [PubMed]
  10. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523–31. https://doi.org/10.1016/S0302-2838(02)00068-4 doi: 10.1016/S0302-2838(02)00068-4. [DOI] [PubMed]
  11. Mowatt G, N’Dow J, Vale L, Nabi G, Boachie C, Cook JA, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 2011;27:3–10. https://doi.org/10.1017/S0266462310001364 doi: 10.1017/S0266462310001364. [DOI] [PubMed]
  12. European Association of Urology. Non-muscle-invasive Bladder Cancer. 2021. URL: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ (accessed June 2021).
  13. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90. https://doi.org/10.1097/01.ju.0000125486.92260.b2 doi: 10.1097/01.ju.0000125486.92260.b2. [DOI] [PubMed]
  14. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709–19. https://doi.org/10.1016/j.eururo.2008.01.015 doi: 10.1016/j.eururo.2008.01.015. [DOI] [PMC free article] [PubMed]
  15. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–70. https://doi.org/10.1097/01.ju.0000034450.80198.1c doi: 10.1097/01.ju.0000034450.80198.1c. [DOI] [PubMed]
  16. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–5. https://doi.org/10.1097/01.ju.0000039680.90768.b3 doi: 10.1097/01.ju.0000039680.90768.b3. [DOI] [PubMed]
  17. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette–Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000;4:CD001986. https://doi.org/10.1002/14651858.CD001986 doi: 10.1002/14651858.CD001986. [DOI] [PMC free article] [PubMed]
  18. National Institute for Health and Care Excellence (NICE). Bladder Cancer: Diagnosis and Management. NICE Guideline [NG2]. London: NICE; 2015. URL: www.nice.org.uk/guidance/ng2 (accessed 11 June 2021).
  19. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005;173:1108–11. https://doi.org/10.1097/01.ju.0000149163.08521.69 doi: 10.1097/01.ju.0000149163.08521.69. [DOI] [PubMed]
  20. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005;95:59–63. https://doi.org/10.1111/j.1464-410X.2005.05249.x doi: 10.1111/j.1464-410X.2005.05249.x. [DOI] [PubMed]
  21. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol 2016;69:438–47. https://doi.org/10.1016/j.eururo.2015.10.024 doi: 10.1016/j.eururo.2015.10.024. [DOI] [PubMed]
  22. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005;173:1318–22. https://doi.org/10.1097/01.ju.0000149080.82697.65 doi: 10.1097/01.ju.0000149080.82697.65. [DOI] [PubMed]
  23. Tan WS, Teo CH, Chan D, Ang KM, Heinrich M, Feber A, et al. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. BJU Int 2020;125:669–78. https://doi.org/10.1111/bju.15008 doi: 10.1111/bju.15008. [DOI] [PMC free article] [PubMed]
  24. Yoshimura K, Utsunomiya N, Ichioka K, Matsui Y, Terai A, Arai Y. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology 2005;65:290–4. https://doi.org/10.1016/j.urology.2004.09.050 doi: 10.1016/j.urology.2004.09.050. [DOI] [PubMed]
  25. Zaak D, Karl A, Knüchel R, Stepp H, Hartmann A, Reich O, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005;96:217–22. https://doi.org/10.1111/j.1464-410X.2005.05604.x doi: 10.1111/j.1464-410X.2005.05604.x. [DOI] [PubMed]
  26. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003;170:428–32. https://doi.org/10.1097/01.ju.0000075054.38441.2d doi: 10.1097/01.ju.0000075054.38441.2d. [DOI] [PubMed]
  27. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010;14(4). https://doi.org/10.3310/hta14040 doi: 10.3310/hta14040. [DOI] [PubMed]
  28. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2011;117:938–47. https://doi.org/10.1002/cncr.25523 doi: 10.1002/cncr.25523. [DOI] [PubMed]
  29. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907–13. https://doi.org/10.1016/j.juro.2010.06.148 doi: 10.1016/j.juro.2010.06.148. [DOI] [PMC free article] [PubMed]
  30. Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58–62. https://doi.org/10.1016/j.juro.2012.03.007 doi: 10.1016/j.juro.2012.03.007. [DOI] [PMC free article] [PubMed]
  31. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae doi: 10.1097/01.sla.0000133083.54934.ae. [DOI] [PMC free article] [PubMed]
  32. National Cancer Institute. CTCAEs v4: Common Terminology Criteria for Adverse Events (CTCAE). Rockville, MD: National Cancer Institute; 2010. URL: http://ctep.cancer.gov/ (accessed 12 February 2021).
  33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509. https://doi.org/10.1080/01621459.1999.10474144 doi: 10.1080/01621459.1999.10474144. [DOI]
  34. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. Process and Methods [PMG9]. London: NICE; 2013. URL: www.nice.org.uk/process/pmg9 (accessed June 2021). [PubMed]
  35. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219–36. https://doi.org/10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P doi: 10.1002/1097-0258(20001215)19:23&#x0003c;3219::AID-SIM623&#x0003e;3.0.CO;2-P. [DOI] [PubMed]
  36. Joint Formulary Committee. British National Formulary. 76th edn. London: BMJ Group and Pharmaceutical Press; 2018.
  37. NHS Improvement. NHS Reference Costs 2018–19. London: NHS Improvement; 2019.
  38. Curtis L, Burns A. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2018.
  39. International Monetary Fund. World Economic Outlook Database (October 2018). URL: www.imf.org/external/pubs/ft/weo/2019/01/weodata/index.aspx (accessed 23 April 2019).
  40. Department of Transport. Transport Analysis Guidance (TAG) Data Book v1.13. 1. London: Department for Transport; 2020. URL: www.gov.uk/government/publications/tag-data-book (accessed June 2021).
  41. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108. https://doi.org/10.1097/00005650-199711000-00002 doi: 10.1097/00005650-199711000-00002. [DOI] [PubMed]
  42. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40. https://doi.org/10.1136/bmj.d40 doi: 10.1136/bmj.d40. [DOI] [PMC free article] [PubMed]
  43. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Chichester: John Wiley & Sons; 2004.
  44. Greene WH. Econometric Analysis: Global Edition. London: Pearson Education UK; 2014.
  45. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40. https://doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W doi: 10.1002/(SICI)1099-1050(199707)6:4&#x0003c;327::AID-HEC282&#x0003e;3.0.CO;2-W. [DOI] [PubMed]
  46. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3(2). https://doi.org/10.3310/hta3020 doi: 10.3310/hta3020. [DOI] [PubMed]
  47. Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377–401. https://doi.org/10.1146/annurev.publhealth.23.100901.140534 doi: 10.1146/annurev.publhealth.23.100901.140534. [DOI] [PubMed]
  48. National Research Council. Principles and Methods of Sensitivity Analyses. In National Research Council (US) Panel on Handling Missing Data in Clinical Trials, editor. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: Academies Press (US); 2010. [PubMed]
  49. Little RJ. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc 1993;88:125–34. https://doi.org/10.1080/01621459.1993.10594302 doi: 10.1080/01621459.1993.10594302. [DOI]
  50. Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat 2013;12:337–47. https://doi.org/10.1002/pst.1549 doi: 10.1002/pst.1549. [DOI] [PubMed]
  51. Permutt T. Sensitivity analysis for missing data in regulatory submissions. Stat Med 2016;35:2876–9. https://doi.org/10.1002/sim.6753 doi: 10.1002/sim.6753. [DOI] [PubMed]
  52. Heer R, Lewis R, Vadiveloo T, Yu G, Mariappan P, Cresswell J, et al. Randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. NEJM Evid 2022;1:10. https://doi.org/10.1056/EVIDoa2200092 doi: 10.1056/EVIDoa2200092. [DOI] [PubMed]
  53. Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, et al. BOXIT – a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004). Eur Urol 2019;75:593–601. https://doi.org/10.1016/j.eururo.2018.09.020 doi: 10.1016/j.eururo.2018.09.020. [DOI] [PubMed]
  54. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749–52. https://doi.org/10.1016/S0022-5347(17)36198-0 doi: 10.1016/S0022-5347(17)36198-0. [DOI] [PubMed]
  55. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5. https://doi.org/10.1016/j.eururo.2005.12.031 doi: 10.1016/j.eururo.2005.12.031. [DOI] [PubMed]
  56. Mariappan P, Lavin V, Phua CQ, Khan SAA, Donat R, Smith G. Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study. Urology 2017;109:134–9. https://doi.org/10.1016/j.urology.2017.08.007 doi: 10.1016/j.urology.2017.08.007. [DOI] [PubMed]
  57. Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR, et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int 2020;125:817–26. https://doi.org/10.1111/bju.15038 doi: 10.1111/bju.15038. [DOI] [PMC free article] [PubMed]
  58. Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. Eur Urol Focus 2020;6:479–89. https://doi.org/10.1016/j.euf.2018.11.005 doi: 10.1016/j.euf.2018.11.005. [DOI] [PubMed]
  59. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 2016;196:1021–9. https://doi.org/10.1016/j.juro.2016.06.049 doi: 10.1016/j.juro.2016.06.049. [DOI] [PubMed]
  60. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53. https://doi.org/10.1016/j.eururo.2013.06.003 doi: 10.1016/j.eururo.2013.06.003. [DOI] [PubMed]
  61. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: an update from the EAU NMIBC Guidelines Panel. Eur Urol 2021;79:480–8. https://doi.org/10.1016/j.eururo.2020.12.033 doi: 10.1016/j.eururo.2020.12.033. [DOI] [PubMed]
  62. Lammers RJ, Palou J, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. BJU Int 2014;114:193–201. https://doi.org/10.1111/bju.12495 doi: 10.1111/bju.12495. [DOI] [PubMed]
  63. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guérin: external validation of the EORTC risk tables. Eur Urol 2011;60:423–30. https://doi.org/10.1016/j.eururo.2011.05.033 doi: 10.1016/j.eururo.2011.05.033. [DOI] [PubMed]
  64. Gravas S, Efstathiou K, Zachos I, Melekos MD, Tzortzis V. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol 2012;19:6269–73. [PubMed]
  65. Kruck S, Bedke J, Hennenlotter J, Amend B, Merseburger A, Stenzl A, Sievert KD. Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics. Urol Int 2011;87:138–42. https://doi.org/10.1159/000328218 doi: 10.1159/000328218. [DOI] [PubMed]
  66. O’Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096–104. https://doi.org/10.1111/bju.12355 doi: 10.1111/bju.12355. [DOI] [PubMed]
  67. Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012;109:1666–73. https://doi.org/10.1111/j.1464-410X.2011.10571.x doi: 10.1111/j.1464-410X.2011.10571.x. [DOI] [PubMed]
  68. Mariappan P, Johnston A, Padovani L, Clark E, Trail M, Hamid S, et al. Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s Quality Performance Indicators Programme. Eur Urol 2020;78:520–30. https://doi.org/10.1016/j.eururo.2020.06.051 doi: 10.1016/j.eururo.2020.06.051. [DOI] [PubMed]
  69. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010;57:595–606. https://doi.org/10.1016/j.eururo.2009.11.041 doi: 10.1016/j.eururo.2009.11.041. [DOI] [PubMed]
  70. Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64:624–38. https://doi.org/10.1016/j.eururo.2013.07.007 doi: 10.1016/j.eururo.2013.07.007. [DOI] [PubMed]
  71. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846–54. https://doi.org/10.1016/j.eururo.2013.03.059 doi: 10.1016/j.eururo.2013.03.059. [DOI] [PubMed]
  72. Konecki T, Kutwin P, Łowicki R, Juszczak AB, Jabłonowski Z. Hexaminolevulinate in the management of nonmuscle invasive bladder cancer: a meta-analysis. Photobiomodul Photomed Laser Surg 2019;37:551–8. https://doi.org/10.1089/photob.2019.4634 doi: 10.1089/photob.2019.4634. [DOI] [PubMed]
  73. Gallagher KM, Gray K, Anderson CH, Lee H, Stewart S, Donat R, Mariappan P. ‘Real-life experience’: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. World J Urol 2017;35:1871–7. https://doi.org/10.1007/s00345-017-2077-6 doi: 10.1007/s00345-017-2077-6. [DOI] [PMC free article] [PubMed]
  74. Mariappan P, Rai B, El-Mokadem I, Anderson CH, Lee H, Stewart S, et al. Real-life experience: early recurrence with Hexvix® photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology 2015;86:327–31. https://doi.org/10.1016/j.urology.2015.04.015 doi: 10.1016/j.urology.2015.04.015. [DOI] [PubMed]
  75. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol 2014;66:863–71. https://doi.org/10.1016/j.eururo.2014.06.037 doi: 10.1016/j.eururo.2014.06.037. [DOI] [PubMed]
  76. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56. https://doi.org/10.1016/j.eururo.2009.04.038 doi: 10.1016/j.eururo.2009.04.038. [DOI] [PubMed]
  77. Palou J, Hernández C, Solsona E, Abascal R, Burgués JP, Rioja C, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. BJU Int 2015;116:37–43. https://doi.org/10.1111/bju.13020 doi: 10.1111/bju.13020. [DOI] [PubMed]
  78. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 2014;11:589–96. https://doi.org/10.1038/nrurol.2014.245 doi: 10.1038/nrurol.2014.245. [DOI] [PubMed]
  79. Cabana MD, Rand CS, Powe NR, Wu AW, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65. https://doi.org/10.1001/jama.282.15.1458 doi: 10.1001/jama.282.15.1458. [DOI] [PubMed]
  80. Sylvester RJ, Canfield SE, Lam TB, Marconi L, MacLennan S, Yuan Y, et al. Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree. Eur Urol 2017;71:811–19. https://doi.org/10.1016/j.eururo.2016.11.023 doi: 10.1016/j.eururo.2016.11.023. [DOI] [PubMed]
  81. Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2016;2:27–36. https://doi.org/10.3233/BLC-150034 doi: 10.3233/BLC-150034. [DOI] [PMC free article] [PubMed]
  82. Leiblich A, Bryant RJ, R McCormick R, Crew J. The management of non-muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol 2018;11:144–8. https://doi.org/10.1177/2051415818757339 doi: 10.1177/2051415818757339. [DOI]
  83. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 Update. Eur Urol 2019;76:639–57. https://doi.org/10.1016/j.eururo.2019.08.016 doi: 10.1016/j.eururo.2019.08.016. [DOI] [PubMed]
  84. Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, et al. Discrepancy between European Association of Urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey. Eur Urol Focus 2019;5:681–8. https://doi.org/10.1016/j.euf.2017.09.002 doi: 10.1016/j.euf.2017.09.002. [DOI] [PubMed]
  85. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette–Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742–50. https://doi.org/10.1111/bju.12012 doi: 10.1111/bju.12012. [DOI] [PMC free article] [PubMed]
  86. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guérin, and bacillus Calmette–Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766–73. https://doi.org/10.1016/j.eururo.2009.12.024 doi: 10.1016/j.eururo.2009.12.024. [DOI] [PMC free article] [PubMed]
  87. Tapiero S, Helfand A, Kedar D, Yossepowitch O, Nadu A, Baniel J, et al. Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer. Urology 2018;118:107–13. https://doi.org/10.1016/j.urology.2018.04.039 doi: 10.1016/j.urology.2018.04.039. [DOI] [PubMed]
  88. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of bacillus Calmette–Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69–76. https://doi.org/10.1016/j.eururo.2013.07.021 doi: 10.1016/j.eururo.2013.07.021. [DOI] [PubMed]
  89. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette–Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72. https://doi.org/10.1016/j.eururo.2012.10.039 doi: 10.1016/j.eururo.2012.10.039. [DOI] [PubMed]
  90. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493–500. https://doi.org/10.1016/j.eururo.2011.05.045 doi: 10.1016/j.eururo.2011.05.045. [DOI] [PubMed]
  91. Chen C, Huang H, Zhao Y, Liu H, Luo Y, Sylvester RJ, et al. Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer. J Cancer 2020;11:1082–93. https://doi.org/10.7150/jca.34527 doi: 10.7150/jca.34527. [DOI] [PMC free article] [PubMed]
  92. Chen C, Huang H, Zhao Y, Liu H, Sylvester R, Lin T, Huang J. Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis. BMJ Open 2019;9:e028173. https://doi.org/10.1136/bmjopen-2018-028173 doi: 10.1136/bmjopen-2018-028173. [DOI] [PMC free article] [PubMed]
  93. Bolenz C, Rother J, Meessen S, Grychtol B, Majlesara A, Gharabaghi N, et al. [The development of real-time multispectral imaging for the diagnostics of bladder cancer.] Urologe A 2019;58:1435–42. https://doi.org/10.1007/s00120-019-01037-3 doi: 10.1007/s00120-019-01037-3. [DOI] [PubMed]
  94. Brunckhorst O, Ong QJ, Elson D, Mayer E. Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review. Surg Endosc 2019;33:1349–67. https://doi.org/10.1007/s00464-018-6578-1 doi: 10.1007/s00464-018-6578-1. [DOI] [PMC free article] [PubMed]
  95. Ikeda A, Nosato H, Kochi Y, Negoro H, Kojima T, Sakanashi H, et al. Cystoscopic imaging for bladder cancer detection based on stepwise organic transfer learning with a pretrained convolutional neural network. J Endourol 2021;35:1030–5. https://doi.org/10.1089/end.2020.0919 doi: 10.1089/end.2020.0919. [DOI] [PubMed]
  96. Tan WS, Tan WP, Tan MY, Khetrapal P, Dong L, deWinter P, et al. Novel urinary biomarkers for the detection of bladder cancer: a systematic review. Cancer Treat Rev 2018;69:39–52. https://doi.org/10.1016/j.ctrv.2018.05.012 doi: 10.1016/j.ctrv.2018.05.012. [DOI] [PubMed]
  97. Leitner CV, Ederer IA, de Martino M, Hofbauer SL, Lucca I, Mbeutcha A, et al. Dynamic prognostication using conditional recurrence and progression estimates for patients with nonmuscle invasive bladder cancer. J Urol 2016;196:46–51. https://doi.org/10.1016/j.juro.2016.01.102 doi: 10.1016/j.juro.2016.01.102. [DOI] [PubMed]
  98. Leo MC, McMullen CK, O’Keeffe-Rosetti M, Weinmann S, Garg T, Nielsen ME. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. Urol Oncol 2020;38:39.e21–39.e27. https://doi.org/10.1016/j.urolonc.2019.10.003 doi: 10.1016/j.urolonc.2019.10.003. [DOI] [PubMed]
  99. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460–6. https://doi.org/10.1038/bjc.2013.372 doi: 10.1038/bjc.2013.372. [DOI] [PMC free article] [PubMed]
  100. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette–Guérin. Eur Urol 2016;69:60–9. https://doi.org/10.1016/j.eururo.2015.06.045 doi: 10.1016/j.eururo.2015.06.045. [DOI] [PubMed]
  101. British Association of Urological Surgeons. BAUS Data & Audit Programme. URL: www.baus.org.uk/professionals/baus_business/data_audit.aspx (accessed 14 January 2022).
  102. Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 2008;5:153–8. https://doi.org/10.1016/j.pdpdt.2008.05.001 doi: 10.1016/j.pdpdt.2008.05.001. [DOI] [PubMed]
  103. National Institute for Health and Care Excellence (NICE). Narrow Band Imaging for Barrett’s Oesophagus. Medtech Innovation Briefing [MIB179]. London: NICE; 2019. URL: www.nice.org.uk/advice/mib179 (accessed 11 June 2021).
  104. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2009.
  105. National Audit Office. Out-of-Hours GP Services in England. London: National Audit Office; 2014. URL: www.nao.org.uk/serarch/out-of-hours/ (accessed 12 January 2022).
  106. HM Revenue and Customs. Travel – Mileage and Fuel Rates and Allowances. 2019. URL: www.gov.uk/government/publications/rates-and-allowances-travel-mileage-and-fuel-allowances/travel-mileage-and-fuel-rates-and-allowances (accessed 11 June 2021).
  107. Department of Health and Social Care. NHS Reference Costs 2009–2010. London: Department of Health and Social Care; 2011. URL: www.gov.uk/government/publications/nhs-reference-costs-2009-2010 (accessed 11 June 2021).
  108. Office for National Statistics (ONS). Annual Survey of Hours and Earnings Time Series of Selected Estimates. Newport: ONS; 2020. URL: www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/ashe1997to2015selectedestimates (accessed 11 June 2021).
  109. NHS Pay Review Body. NHS Pay Review Body Twenty-sixth Report 2012. London: The Stationery Office; 2012. URL: www.gov.uk/government/publications/nhs-pay-review-body-twenty-sixth-report-2012 (accessed 11 June 2021).
  110. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making 2012;32:690–700. https://doi.org/10.1177/0272989X12455463 doi: 10.1177/0272989X12455463. [DOI] [PubMed]
  111. Office for National Statistics (ONS). National Life Tables, UK: 2016 to 2018. Newport: ONS; 2019. URL: www.ons.gov.uk/releases/nationallifetablesuk2016to2018 (accessed June 2021).
  112. EuroQol Research Foundation. EQ-5D-3L User Guide, 2018. Rotterdam: EuroQol Research Foundation; 2018.
  113. Kaltenthaler E, Tappenden P, Paisley S, Squires H. NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-effectiveness Models. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2011. [PubMed]
  114. Gray AM, Clarke PM, Wolstenholme J, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Healthcare. Oxford: Oxford University Press; 2011.
  115. Committee for Medicinal Products for Human Use. Guideline on Adjustment for Baseline Covariates in Clinical Trials. London: European Medicines Agency; 2015.
  116. Shen J, Hill S, Mott D, Breckons M, Vale L, Pickard R. Conducting a time trade-off study alongside a clinical trial: a case study and recommendations. Pharmacoecon Open 2019;3:5–20. https://doi.org/10.1007/s41669-018-0084-1 doi: 10.1007/s41669-018-0084-1. [DOI] [PMC free article] [PubMed]
  117. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15:209–31. https://doi.org/10.1016/0167-6296(95)00038-0 doi: 10.1016/0167-6296(95)00038-0. [DOI] [PubMed]
  118. Gandhi M, Rand K, Luo N. Valuation of health states considered to be worse than death – an analysis of composite time trade-off data from 5 EQ-5D-5L valuation studies. Value Health 2019;22:370–6. https://doi.org/10.1016/j.jval.2018.10.002 doi: 10.1016/j.jval.2018.10.002. [DOI] [PubMed]
  119. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986;5:1. https://doi.org/10.1016/0167-6296(86)90020-2 doi: 10.1016/0167-6296(86)90020-2. [DOI] [PubMed]
  120. Janssen BM, Oppe M, Versteegh MM, Stolk EA. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ 2013;14(Suppl. 1):5–13. https://doi.org/10.1007/s10198-013-0503-2 doi: 10.1007/s10198-013-0503-2. [DOI] [PMC free article] [PubMed]
  121. Gudex C. Time Trade-off User Manual: Props and Self-completion Methods. York: Centre for Health Economics, University of York; 1994.
  122. Miremami J, Kyprianou N. The promise of novel molecular markers in bladder cancer. Int J Mol Sci 2014;15:23897–908. https://doi.org/10.3390/ijms151223897 doi: 10.3390/ijms151223897. [DOI] [PMC free article] [PubMed]
  123. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22. https://doi.org/10.1038/nature12965 doi: 10.1038/nature12965. [DOI] [PMC free article] [PubMed]
  124. Great Britain. Human Tissue Act 2004. London: The Stationery Office; 2004.
  125. NHS Health Research Authority. Hyperthermia for Intermediate risk bladder cancer (HIVEC-II). URL: www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/hyperthermia-for-intermediate-risk-bladder-cancerhivec-ii/ (accessed 14 January 2022).
  126. Tan WS, Feber A, Dong L, Sarpong R, Rezaee S, Rodney S, et al. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells. BMC Cancer 2017;17. https://doi.org/10.1186/s12885-017-3758-7 doi: 10.1186/s12885-017-3758-7. [DOI] [PMC free article] [PubMed]

RESOURCES